Earnings ·
HUTCHMED (China) Limited reported total revenue of $278.3 million for the six months ended June 30, 2026, a flat…
HCMHUTCHMED (China) Ltd
HUTCHMED (China) Limited reported total revenue of $278.3 million for the six months ended June 30, 2026, a flat change compared to $277.7 million in H1-25. Oncology/Immunology consolidated revenue grew 23% to $162.3 million, driven by strong China sales of ELUNATE® ($47.1 million) and SULANDA® ($18.4 million), alongside a $18.1 million milestone payment from Eli Lilly. Net income attributable to HUTCHMED was $15.9 million, down significantly from $455.0 million in H1-25 which included a $416.3 million gain on the divestment of 45% of Shanghai Hutchison Pharmaceuticals Limited. The company maintains a cash balance of $1.37 billion and reiterates full-year 2026 Oncology/Immunology revenue guidance of $330 million to $450 million. HUTCHMED is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases.